Abstract BACKGROUND: The Ayurvedic concept of Ama refers to the accumulation of incompletely digested or metabolized substances in the body due to impaired Agni (digestive fire). Ama is described as a pathological entity that disrupts systemic homeostasis, leading to chronic metabolic and immune disorders. Modern medical science recognizes similar pathological processes, such as endotoxin accumulation, gut dysbiosis, metabolic endotoxemia, and inflammatory responses driven by advanced glycation end-products (AGEs), damage-associated molecular patterns, and oxidative stress. Despite advances in research and clinical interventions, metabolic and immune disorders like diabetes, metabolic dysfunction-associated fatty liver disease, inflammatory bowel disease, and autoimmune conditions continue to rise globally. Expanding the scope of Ama and its subtypes in relation to these disorders may provide novel insights for disease prevention, diagnostics, and therapeutic approaches. EXISTING KNOWLEDGE AND GAP: Ayurvedic texts elaborate on Ama as a primary etiological factor in disease progression, classifying it based on its origins, affinity, and systemic translocation. However, there is a lack of standardized clinical assessment tools to evaluate Ama in the context of modern disease models. Current biomedical research highlights the crucial role of gut health, intestinal permeability, microbial dysbiosis, and metabolic endotoxemia in the development of chronic diseases. Despite these parallels, there is minimal integrative research correlating Ama with measurable biochemical or molecular markers. Moreover, the role of Ama in immune activation and inflammatory disorders remains largely unexplored within a scientific framework. PROPOSED CONCEPT: This paper proposes an expanded classification of Ama , integrating Ayurvedic epistemology with modern biomedical understanding. Ama can be characterized as a gut-derived response antigen complex or gut-associated molecular complex, which includes toxic metabolites, undigested peptides, microbial toxins, and inflammatory mediators resulting from impaired digestion and absorption. The subtypes of Ama can be categorized based on the site of expression, cause of origin, specificity or affinity, Kaal , and its movement or translocation. Modern tools such as metabolomics, proteomics, transcriptomics, and computational systems biology models can be employed to validate Ama and its subtypes. Biomarkers such as HbA1c (paralleling Ama in diabetes), lipid oxidation markers, gut microbiome alterations, and inflammatory cytokines may serve as objective correlates of Ama . WAY FORWARD: Future research should focus on developing standardized clinical scales for Ama assessment, incorporating radiological, biochemical, molecular, and genetic markers. Systems biology approaches, such as network pharmacology and artificial intelligence-based predictive models, should be utilized to map the progression of Ama in metabolic and immune disorders. Ayurvedic interventions, such as Deepana, Pachana , and Shodhana therapies, should be studied for their impact on gut barrier function, microbiome modulation, and immune homeostasis. Bridging Ayurvedic concepts with modern scientific methodologies will enable the development of personalized diagnostic and therapeutic strategies for chronic diseases.
Ovulatory disorders account for 18–25% of infertility cases, with PCOS being the most common cause. Beeja Dushti, described by Acharya Sushruta as a key factor in Garbha Sambhava Samagri, emphasizes the importance of normal ovum development and function. Nasya Karma, a Panchakarma therapy plays major role in this. Case Presentation: This case series includes five female patients aged between 20 to 35 years, presenting with infertility of 1-5 years duration. Diagnosed patients of anovulation were taken. After informed consent, Nasya Karma with Kshirbala (101 Avarthi) Taila was administered for 14 days as per classical guidelines. Results: Post-treatment evaluation revealed improvement in follicular development and ovulatory patterns in 4 patients. Regularization of menstrual cycles was observed in 5 patients. Conclusion: The present case series suggests that Nasya Karma is a safe and potentially effective therapeutic modality in the management of anovulatory infertility. However, larger clinical trials are required to validate these findings and establish standard treatment protocols.
Sandhigata Vata, correlated to osteoarthritis of the knee joint, is a common degenerative disorder predominantly affecting the middle-aged (>40yrs) and elderly population. It is characterized by Vatapurnadrutisparsha, Sandhi sotha and Prasarana akunchana pravruti savedana due to vitiation of Vata Dosha. Ayurvedic classics emphasize Snehana and Swedana as prime modalities in its management. Janu Basti, a localized external therapy, provides both these effects and is widely used in clinical practice. Objectives: To assess the efficacy of Janu Basti with Masha Taila as well as internal administration of Phalatrikadi Churna in the management of Sandhigata Vata. Methodology: A total of 31 patients were registered for the study, out of which 30 completed the treatment. Janu Basti was administered using Masha Taila for 7 days followed by a 7 days gap then again for 7 days, along with Phalatrikadi Churna (5gm twice daily after food with lukewarm water). Analysis was carried out based on subjective parameters such as Vatapurnadrutisparsha,Sandhi sotha, tenderness and Prasarana akunchana pravruti savedana, loss of flexibility along with objective parameters like ESR, TLC, and differential count. Statistical analysis was made using paired t-test. Results interpretation and discussion: From the study it is found that 36.67%patients were having marked improvement, 53.33% were moderate improvement and 10% mild improvement. Conclusion: Masha Taila (Janu Basti), with Phalatrikadi Churna, is an effective and safe therapeutic approach in the management of Sandhigata Vata. It significantly decreases symptoms and improves joint function.
Pandu Roga is described in Ayurveda as a disorder caused by Dosha vitiation, predominantly Pitta. However, Vataja Pandu presents with features such as weakness, anorexia, dryness, blackish discoloration, and emaciation. Pancytopenia, characterized by a reduction in red blood cells, white blood cells, and platelets, can be correlated with Vataja Pandu involving Rasa, Rakta, and Majja Dhatu Kshaya along with Ojas depletion. A 38-year-old female presented with generalized weakness, pallor, dyspnea on exertion, blackish skin discoloration, and loss of appetite for two years. Hematological investigations confirmed pancytopenia. Based on Ayurvedic assessment, the condition was diagnosed as Vataja Pandu. Treatment included Panchatikta Ghrita, Guggulu preparations, Rohitakarishta, dietary regulation, and lifestyle modifications, focusing on Agni Deepana, Vata Shamana, Rakta Vardhana, and Rasayana therapy. Progressive improvement in appetite, strength, and hematological parameters was observed without adverse effects. This case demonstrates the potential of Ayurveda in managing pancytopenia through a holistic and root-cause-based approach.
As generative artificial intelligence (AI) moves toward large-scale healthcare deployment, a central challenge is how to harness its benefits without eroding clinical expertise or accountability. This commentary, written from clinician and technologist perspectives, argues that responsible AI adoption must rest on two foundations: preserving human accountability for medical decisions and integrating machine learning with structured, explainable reasoning. AI offers significant promise in diagnostics, personalized therapeutics, workflow automation, and burnout reduction. Data-driven discovery and biotechnology advances further expand therapeutic possibilities. However, risks include hallucinations, automation bias, and progressive deskilling. Emerging evidence suggests sustained AI assistance may diminish unaided diagnostic reasoning, underscoring the need for safeguards that maintain core clinical skills. From an implementation standpoint, success depends less on technical novelty than on integration within established care pathways, regulatory clarity, and demonstrable safety. Governments and large health systems are well positioned to scale validated solutions. The most sustainable path forward is hybrid “neuro-symbolic” systems that combine generative AI’s conversational capabilities with transparent, probabilistic clinical reasoning. Trustworthy healthcare AI must remain explainable, auditable, and decisively human-led.